Summary
Ublituximab, an intravenous glycoengineered chimeric anti-CD20 IgG1 monoclonal antibody
(mAb), is a new FDA-approved treatment for relapsing forms of Multiple Sclerosis (MS).
Reassembling the other three anti-CD20 mAbs already in use for MS (rituximab, ocrelizumab
and ofatumumab), ublituximab leads to depletion of B cells but spars long-lived plasma
cells. Here, we discuss the main findings obtained during the phase 3 clinical trials
(ULTIMATE I and II) for ublituximab versus teriflunomide. The current emergence and
approval of new anti-CD20 mAbs with different dose regimens, routes of application,
glycoengineering and mechanisms of action may contribute to different clinical outcomes.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Multiple Sclerosis and Related DisordersAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Neutralizing antibodies and antidrug antibodies in the ublituximab phase 3 ULTIMATE I and II studies in relapsing multiple sclerosis.Mult. Scler. J. 2022; 28 ([abstract no. P103 plus poster])67
- Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study.Mult. Scler. J. 2022; 28: 910-924https://doi.org/10.1177/13524585211044479
- Rituximab in multiple sclerosis: frequency and clinical relevance of anti-drug antibodies.Mult. Scler. J. 2018; 24: 1224-1233https://doi.org/10.1177/1352458517720044
- Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: results from ASCLEPIOS I and II.Mult. Scler. J. 2022; 28: 1562-1575https://doi.org/10.1177/13524585221078825
- Ofatumumab versus teriflunomide in multiple sclerosis.N. Engl. J. Med. 2020; 383: 546-557https://doi.org/10.1056/NEJMoa1917246
- Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis.N. Engl. J. Med. 2017; 376: 221-234https://doi.org/10.1056/NEJMoa1601277
- Association of higher ocrelizumab exposure with reduced disability progression in multiple sclerosis.Neurol. Neuroimmunol. Neuroinflammation. 2023; 10e200094https://doi.org/10.1212/NXI.0000000000200094
- B-cell depletion with rituximab in relapsing–remitting multiple sclerosis.N. Engl. J. Med. 2008; 358: 676-688https://doi.org/10.1056/NEJMoa0706383
- Ocrelizumab treatment modulates B-cell regulating factors in multiple sclerosis.Neurol. Neuroimmunol. Neuroinflammation. 2023; 10e200083https://doi.org/10.1212/NXI.0000000000200083
- Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials.JAMA Neurol. 2020; 771132https://doi.org/10.1001/jamaneurol.2020.1568
- B cells in MS and NMO: pathogenesis and therapy.Semin. Immunopathol. 2014; 36: 339-350https://doi.org/10.1007/s00281-014-0424-x
- CD20+ T cells as pathogenic players and therapeutic targets in MS.Ann. Neurol. 2021; 90: 722-724https://doi.org/10.1002/ana.26232
- Ocrelizumab versus placebo in primary progressive multiple sclerosis.N. Engl. J. Med. 2017; 376: 209-220https://doi.org/10.1056/NEJMoa1606468
- Proinflammatory CD20 + T cells contribute to CNS-directed autoimmunity.Sci. Transl. Med. 2022; 14: 1-11https://doi.org/10.1126/scitranslmed.abi4632
- Ublituximab: a new anti-CD20 agent for multiple sclerosis.Lancet Neurol. 2022; 21: 1070-1072https://doi.org/10.1016/S1474-4422(22)00446-X
- Faster B-cell repletion after anti-CD20 infusion in Black patients compared to white patients with neurologic diseases.Mult. Scler. Relat. Disord. 2022; https://doi.org/10.1016/j.msard.2022.103830
- BMI influences CD20 kinetics in multiple sclerosis patients treated with ocrelizumab.Mult. Scler. Relat. Disord. 2020; 43102186https://doi.org/10.1016/j.msard.2020.102186
- Ublituximab versus teriflunomide in relapsing multiple sclerosis.N. Engl. J. Med. 2022; 387: 704-714https://doi.org/10.1056/NEJMoa2201904
- Anti-rituximab antibodies demonstrate neutralizing capacity, associate with lower circulating drug levels and earlier relapse in lupus.Rheumatology. 2022; (A95.2-A96.)https://doi.org/10.1093/rheumatology/keac608
Article info
Publication history
Published online: April 25, 2023
Accepted:
April 24,
2023
Received in revised form:
April 12,
2023
Received:
March 2,
2023
Identification
Copyright
© 2023 Elsevier B.V. All rights reserved.
